STOCK TITAN

I-Mab - $IMAB STOCK NEWS

Welcome to our dedicated page for I-Mab news (Ticker: $IMAB), a resource for investors and traders seeking the latest updates and insights on I-Mab stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect I-Mab's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of I-Mab's position in the market.

Rhea-AI Summary

I-Mab (NASDAQ: IMAB) has announced the appointment of Dr. Phillip Dennis as Chief Medical Officer, effective June 17, 2024. Dr. Dennis will lead I-Mab's global clinical development and join the Executive Leadership Team. With two decades of oncology drug development experience, including key roles at Sanofi and AstraZeneca, Dr. Dennis brings significant expertise. His appointment aims to advance I-Mab's clinical pipeline, particularly for treatments like uliledlimab, givastomig, and ragistomig. Before his industry roles, Dr. Dennis was a professor at Johns Hopkins University and a senior investigator at the US National Cancer Institute.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
management
-
Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a global biotech company, has announced a clinical trial collaboration with Bristol Myers Squibb (NYSE: BMY). The focus is on evaluating the combination of givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, with nivolumab and chemotherapy for treating advanced gastric and esophageal cancers. The collaboration leverages promising safety and efficacy data from givastomig's monotherapy study, presented at the European Society of Medical Oncology Congress 2023. The multi-national Phase 1 study will be conducted by I-Mab, with Bristol Myers Squibb supplying nivolumab. The aim is to explore the potential of this combination as a first-line treatment for Claudin 18.2-positive cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
Rhea-AI Summary

I-Mab (NASDAQ: IMAB) announced promising Phase 1 clinical data for its bispecific antibody ragistomig (PD-L1x4-1BB) at the 2024 ASCO Annual Meeting. The data revealed a manageable safety profile and encouraging efficacy in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR). Ragistomig demonstrated an overall response rate (ORR) of 25% at the optimal dose of 5 mg/kg, with a clinical benefit rate (CBR) of 75%. The study included patients with advanced or relapsed/refractory solid tumors, with 71.4% of responders having received prior anti-PD-(L1) therapy. I-Mab highlighted the potential of ragistomig as both monotherapy and in combination with other treatments. The data will be presented by Dr. Gerald Falchook on June 1, 2024, at the ASCO meeting in Chicago.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in immunotherapies for cancer treatment, announced its participation in the Jefferies Global Healthcare Conference on June 5, 2024.

Key presenters include CEO Raj Kannan and Interim CMO Louie Naumovski, with the presentation scheduled for 9:30 a.m. EST. The event will feature one-on-one and small group meetings with key management members, including CFO Joe Skelton and Senior Director of Investor Relations Tyler Ehler.

The presentation will be available via webcast on I-Mab's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

I-Mab, a global biotech company, filed its 2023 annual report on Form 20-F with the SEC. The report focuses on the development of immunotherapies for cancer treatment. It can be accessed on the company's investor relations website and the SEC's website. Shareholders and ADS holders can request hard copies free of charge.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
-
Rhea-AI Summary
I-Mab (IMAB) to present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024, focusing on immunotherapies for cancer treatment. The presentation will feature key executives and offer opportunities for one-on-one meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
conferences
Rhea-AI Summary
I-Mab successfully closes divestiture transaction transferring equity interest in I-Mab Shanghai, with a total consideration of up to US$80 million. The Company extinguishes repurchase obligations of approximately US$183 million and participates in Series C fundraising of the Hangzhou Company for US$19 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
Rhea-AI Summary
I-Mab reports positive clinical results for uliledlimab and givastomig, plans strategic divestiture in China, and discloses financial results for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
-
Rhea-AI Summary
I-Mab (IMAB) has entered into definitive agreements to divest its assets and business operations in China, marking a strategic shift to become a U.S.-based biotech. The agreement provides for a focus on advancing oncology clinical assets, reducing operational costs, and retaining cash in hand, while streamlining the operating model. The company retains ex-China rights to clinical stage assets and aims to remain listed on NASDAQ. The Hangzhou Company will acquire I-Mab drug assets in China, and the Company will participate in the Series C fundraising of the Hangzhou Company for an equity interest subscription of US$19 million in cash. Management and personnel changes include the appointment of an Interim Chairperson and a new Chief Financial Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
Rhea-AI Summary
I-Mab, a global biotechnology company, will be participating in two conferences in November 2023: the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. The company's CEO, Dr. Raj Kannan, and CMO, Dr. John Hayslip, will be presenting at both conferences. The conferences will provide opportunities for one-on-one and small group meetings with management. The webcast of the Jefferies conference will be available on I-Mab's IR website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
none
I-Mab

Nasdaq:IMAB

IMAB Rankings

IMAB Stock Data

150.44M
122.60M
1.06%
35.07%
1.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Shanghai

About IMAB

i-mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. it is developing felzartamab (tj202), a cd38 antibody that is in phase iii clinical trials to treat multiple myeloma and autoimmune diseases; eftansomatropin (tj101), a long-acting human growth hormone that has completed phase ii clinical trials to treat pediatric growth hormone deficiency; and olamkicept (tj301), a il-6 blocker, which is in phase ii clinical trials for the treatment of ulcerative colitis and autoimmune diseases. the company's product candidates also include enoblituzumab, a humanized b7-h3 antibody that has completed phase i clinical trials to treat head and neck cancer and other oncology diseases; efineptakin (tj107), a long-acting recombinant human il-7, which is in phase 2 clinical trials to treat glioblastoma multiforme (gbm